Welcome to the TLDR Biotech newsletter!

TLDR Biotech aims to be your one-stop source for biotech and pharma updates - all with one daily email.

I’m always looking to make these news compilations more informative, impactful, and easy to navigate.

So if you have any feedback on what you like (or don’t), I’d love to hear from you!

(You can also reach out to me on LinkedIn)

MINOR HOUSEKEEPING
How these updates are formatted

The newsletter is split into three main sections:

• THE GOOD - good news (eg. fundraises, product approvals)

• THE BAD - negative news (eg. clinical trial failures, layoffs)

• THE UGLY - negative but atypical news (lawsuits, product recalls, scandals)

Within each of the three above parts, there are additional sections for easier navigation:

• Eg. There will be multiple “The Good” sections covering things like Fundraises, Approvals, Partnerships etc.

• There will be also additional tags within these sections (Eg. fundraises may mention Stage, product approvals may mention drug name and disease area.)

See something you want to get into further? Click the Read More (goes out to either a news article or a press release).

One last thing; I know paywalls can be annoying, so there’s a new [Paywall] tag for any news stories behind one.

ENJOYING THESE NEWSLETTERS?
Consider an optional paid subscription.

TLDR Biotech is currently a one-person show that works full-time to put together these compilations and related content.

If you’re getting value out of these daily compilations, please consider a paid subscription (only $5/month) to support my continued work on this project.

THE GOOD
Approvals & Labels

Amgen lands FDA accelerated approval for small cell lung cancer drug
Bispecific antibody, lung cancer - Read more

Bristol Myers Squibb lands FDA accelerated approval for CAR-T therapy
Cell therapy, cancer, lymphoma - Read more

Karius nabs FDA breakthrough tag for infectious disease blood test
Diagnostics, disease detection - Read more

THE GOOD
Clinical Trials

Roche’s $2.7B foray into weight-loss yields Ph1 win
GLP-1, obesity - Read more

Eli Lilly’s double-double Ph3 win for once-weekly insulins shots
Diabetes, insulin - Read more

Pfizer, Arvinas touts promising Ph1b breast cancer data
Small molecule, breast cancer - Read more [Paywall]

AstraZeneca’s COVID-19 antibody delivers Ph3 win
COVID-19, antibody - Read more 

THE GOOD
Company Launches

Challenger approaching; Hercules CM NewCo enters obesity field with $400M launch
GLP-1, GIP, obesity - Read more

THE GOOD
Earnings & Finances

Lundbeck’s depression med grows despite FDA-imposed DTC blackout
Small molecule, depression - Read more

THE GOOD
Fundraises

Phenomix Sciences $7.8M raise
Diagnostic test, precision medicine, obesity - Read more

CinDome Pharma $40M Series B Extension
Small molecule, chronic gastroparesis - Read more

Metabolon $60M credit facilty
Metabolomics, precision medicine - Read more

SPONSORED
Looking to leave the lab and get into sales?

One of the biggest hurdles to overcome in this job market is experience - and the next best thing you can do is get certified in life sciences sales skills.

Succession is running a 4-week “Welcome to Sales Accelerator” to give you the skills you need and help you land your first sales role. Ready to launch your life science sales career? (Spots are filling up for the June cohort.)

THE GOOD
IPOs

Monte Rosa Therapeutics names IPO price, expects $100M raise
Small molecule, cancer, autoimmune, inflammatory - Read more

THE GOOD
Markets Reports

Eli Lilly leads pack in YoY revenue gains, report
Revenue growth rankings - Read more 

THE GOOD
Marketing

First Wave’s second go-around, rebrands to Entero Therapeutics
Recombinant protein, celiac disease - Read more

THE GOOD
Mergers & Acquisitions

J&J snags Proteologix for cool $850M
Bispecific antibody, atopic dermatitis - Read more

Absolutely!; Absolute Biotech merges with Vector Laboratories
Reagents, instrumentation, antibody - Read more

THE GOOD
Opinions

Biogen’s CEO likes a challenge, welcomes Eli Lilly’s Alzheimer’s challenge
Antibody, Alzheimer’s - Read more [Paywall]

Eli Lilly DTC play has big pharma thinking, Novartis included
Online pharmacy, direct-to-customer - Read more [Paywall]

THE GOOD
Partnerships

Association of Cancer Care Center’s and Flatiron Health partnership
Clinical trial access, clinical trial data capture, cancer - Read more

Galapagos partners with Blood Centers of America
CAR-T manufacturing, decentralization - Read more

GSK partners on new initiative fighting AMR, £45m pledged
Antimicrobial resistance - Read more

THE GOOD
Politics & Policy

Washington lawmakers reauthorize FDA’s pediatric voucher program
Priority review vouchers, pediatric rare diseases - Read more [Paywall]

THE GOOD
Product Launches

Thermo Fisher Scientific launches new blood screening test
Blood type, diagnostic screening - Read more

THE BAD
Business Development

GSK dumps last bit of stock from spin-off Haleon
Consumer health - Read more

THE BAD
Clinical Trials

Biogen, Ionis scrap ALS program after disappointing study results
Oligonucleotide, ALS - Read more

THE BAD
Partnerships

Roche’s Angelman out-licensing “advanced” talks fall through
Oligonucleotide, Angelman syndrome - Read more [Paywall]

Alexion returns asset to Zealand, citing “business reasons”
Peptides, complement disorders - Read more

THE UGLY
Accidents & Natural Disasters

Fire at under-construction Novo Nordisk site; no injuries
Building fire - Read more

THE UGLY
Criminal Acts

Former Sandoz exec dodges jail in price-fixing case
Generics, price-fixing - Read more

THE UGLY
Lawsuits

AstraZeneca faces continued unequal pay court cases
Unequal pay, gender pay gap - Read more

THE UGLY
Politics & Policy

Senator Bernie Sanders slams weight loss drug makers, writes they could “bankrupt American health care”
Prescription drug pricing, obesity - Read more

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣 

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

And if you like this newsletter and think a friend or colleague would benefit, please share this with them! ♻️

Want to sponsor this newsletter and reach an audience of 100+ biotech and pharma professionals? Reach us here. 👍

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here. 🔍